Market capitalization | $93.51m |
Enterprise Value | $2.52m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.14 |
P/S ratio (TTM) P/S ratio | 5.03 |
P/B ratio (TTM) P/B ratio | 0.89 |
Revenue growth (TTM) Revenue growth | 514.08% |
Revenue (TTM) Revenue | $18.58m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
7 Analysts have issued a Generation Bio Co forecast:
7 Analysts have issued a Generation Bio Co forecast:
Sep '24 |
+/-
%
|
||
Revenue | 19 19 |
513%
513%
|
|
Gross Profit | 14 14 |
697%
697%
|
|
EBITDA | -85 -85 |
34%
34%
|
EBIT (Operating Income) EBIT | -90 -90 |
33%
33%
|
Net Profit | -145 -145 |
17%
17%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Generation Bio Co., a genetic medicines company, develops gene therapies for the treatment of rare and prevalent diseases. The company is developing a portfolio of eight programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was founded in 2016 and is headquartered in Cambridge, Massachusetts.
Head office | United States |
CEO | Cameron McDonough |
Employees | 174 |
Founded | 2016 |
Website | www.generationbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.